1.7464
price up icon15.09%   0.2264
 
loading
C 4 Therapeutics Inc stock is traded at $1.7464, with a volume of 502.68K. It is up +15.09% in the last 24 hours and up +1.12% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
See More
Previous Close:
$1.52
Open:
$1.53
24h Volume:
502.68K
Relative Volume:
0.47
Market Cap:
$111.48M
Revenue:
$20.76M
Net Income/Loss:
$-132.49M
P/E Ratio:
-0.6541
EPS:
-2.67
Net Cash Flow:
$-108.55M
1W Performance:
+15.85%
1M Performance:
+1.12%
6M Performance:
-54.44%
1Y Performance:
-60.51%
1-Day Range:
Value
$1.53
$1.75
1-Week Range:
Value
$1.43
$1.75
52-Week Range:
Value
$1.085
$7.66

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name
Name
C 4 Therapeutics Inc
Name
Phone
(617) 231-0700
Name
Address
490 ARSENAL WAY, WATERTOWN
Name
Employee
110
Name
Twitter
Name
Next Earnings Date
2025-02-24
Name
Latest SEC Filings
Name
CCCC's Discussions on Twitter

Compare CCCC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CCCC
C 4 Therapeutics Inc
1.7494 111.48M 20.76M -132.49M -108.55M -2.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
467.58 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.25 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
323.11 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.00 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.61 28.51B 3.81B -644.79M -669.77M -6.24

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-19-24 Upgrade Wells Fargo Equal Weight → Overweight
Nov-18-24 Initiated Stephens Equal-Weight
Jan-29-24 Upgrade JP Morgan Underweight → Neutral
Dec-13-23 Upgrade Stifel Hold → Buy
Feb-24-23 Upgrade Credit Suisse Underperform → Neutral
Feb-24-23 Downgrade JP Morgan Neutral → Underweight
Nov-04-22 Downgrade JP Morgan Overweight → Neutral
Oct-11-22 Initiated Morgan Stanley Underweight
Apr-28-22 Initiated Credit Suisse Underperform
Apr-11-22 Downgrade BofA Securities Buy → Neutral
Mar-10-22 Initiated JP Morgan Overweight
Feb-11-22 Resumed BMO Capital Markets Outperform
Feb-10-22 Initiated Wells Fargo Equal Weight
Nov-23-21 Initiated BofA Securities Buy
Oct-14-21 Initiated SVB Leerink Mkt Perform
Sep-30-21 Initiated Stifel Hold
Jun-04-21 Initiated H.C. Wainwright Buy
Mar-31-21 Initiated BMO Capital Markets Outperform
Oct-28-20 Initiated UBS Buy
Oct-27-20 Initiated BMO Capital Markets Outperform
Oct-27-20 Initiated Jefferies Buy
View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

pulisher
Jun 18, 2025

C4 Therapeutics Holds Annual Stockholders Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 17, 2025

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 17, 2025
pulisher
Jun 17, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 17, 2025
pulisher
Jun 16, 2025

C4 Therapeutics: An Entry Point If There's Ever Going To Be One - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint Pharmaceuticals

Jun 16, 2025
pulisher
Jun 13, 2025

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 13, 2025
pulisher
Jun 13, 2025

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Jun 13, 2025
pulisher
Jun 12, 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 12, 2025
pulisher
Jun 10, 2025

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 10, 2025
pulisher
Jun 10, 2025

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Jun 10, 2025
pulisher
Jun 09, 2025

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 09, 2025
pulisher
Jun 06, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 06, 2025
pulisher
Jun 06, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Jun 06, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 06, 2025
pulisher
Jun 05, 2025

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 05, 2025
pulisher
Jun 03, 2025

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Biotech Startup Xilio Awards $194K Worth of Stock Options Under Nasdaq Compliance Plan - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 03, 2025
pulisher
Jun 03, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 03, 2025
pulisher
Jun 02, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView

Jun 02, 2025
pulisher
Jun 02, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Jun 02, 2025
pulisher
Jun 02, 2025

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 02, 2025
pulisher
May 30, 2025

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView

May 30, 2025
pulisher
May 22, 2025

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - Yahoo Finance

May 22, 2025
pulisher
May 21, 2025

C4 Therapeutics patents new B-Raf V600E mutant degradation inducers - BioWorld MedTech

May 21, 2025
pulisher
May 16, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint Pharmaceuticals

May 16, 2025
pulisher
May 15, 2025

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - TradingView

May 15, 2025
pulisher
May 12, 2025

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph

May 12, 2025
pulisher
May 12, 2025

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

May 12, 2025
pulisher
May 08, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

C4 Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 08, 2025
pulisher
May 08, 2025

Cemsidomide Combo May Produce Responses in Multiple Myeloma - CancerNetwork

May 08, 2025

C 4 Therapeutics Inc Stock (CCCC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

C 4 Therapeutics Inc Stock (CCCC) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Boyle Scott N
Chief Business Officer
Feb 14 '25
Sale
3.15
490
1,544
110,842
$21.01
price up icon 1.80%
$35.71
price down icon 0.18%
$22.83
price up icon 0.62%
$96.88
price down icon 0.67%
$111.47
price up icon 0.91%
biotechnology ONC
$243.50
price up icon 0.85%
Cap:     |  Volume (24h):